Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Our products& pipeline
    • Diseases we target
    • GS010 for LHON
    • GS030 for Retinitis Pigmentosa
    • GS030 for Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
  • Investors& media
    • Company Overview
    • Press releases
    • Events & presentations
    • News and press coverage
    • Stock information
    • Governance
    • Documentation

Finance

29 April 2022

GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

21 April 2022

GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

08 April 2022

GenSight Biologics Reports Full Year 2021 Consolidated Financial Results

11 March 2022

GenSight Biologics Announces its 2022 Financial Calendar

04 Oct 2021 - 05 Oct 2021

Chardan 5th Annual Genetic Medicines Conference – virtual

04 October 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ASRS, ESGCT and Several Investor and Industry Meetings in October

07 Sep 2021

Redburn Gene Therapy Virtual Summit 2021

01 September 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

29 July 2021

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

05 July 2021

GenSight Biologics Announces Approval of the LUMEVOQ® Cohort Temporary Authorization for Use (ATUc) in France

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • View next 9 articles
© 2022 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page